2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2912

Integrating Patient Electronic Health Records With An Electronic Data Capture System In a Biologics Registry For Inflammatory Arthritides
Abstract Number: 2735

Integrative Analysis Of Multiple Omics Technologies Reveals a Novel Therapeutic Target For Rheumatoid Arthritis (RA)
Abstract Number: 978

Inter-Professional Training Programs For Primary Care Providers Can Successfully Educate Practitioners With Dramatically Different Educational and Training Background Through a Common Mini-Residency Training Program
Abstract Number: 2187

Inter-Rater Reliability Of Jumping Mechanography In Healthy Children and Adults
Abstract Number: 2657

Interactions Between Cigarette Smoking, Body Mass Index and Inflammatory Cytokine Levels In Determining The Risk Of Developing Rheumatoid Arthritis
Abstract Number: 69

Interconnected Cellular Projections and Gap Junctions Mediate Metabolic Coupling Between Chondrocytes Located In Different Layers Of The Tissue: Cell-To-Cell Communication In Normal and Osteoarthritic Cartilage
Abstract Number: 713

Interferon Regulatory Factor 2 Haploinsufficiency Deteriorates Imiquimod-Induced Psoriasis-Like Skin Inflammation
Abstract Number: 1899

Interferon Regulatory Factor 5 Gene Variant rs2004640 Is Associated With Carotid Intimal Medial Thickness In Rheumatoid Arthritis Patients
Abstract Number: 1616

Interferon Regulatory Factors 3 and 5 As Key Elements Of The Interferon Signature On Plasmacytoid Dendritic Cells From Systemic Lupus Erythematosus Patients
Abstract Number: 1656

Interferon Type I and T Helper 17: A Dangerous Liaison In Primary Sjögren’s Syndrome?
Abstract Number: 2082

Interferon-Regulated Chemokine and Innate Cytokine Scores Identify Refractory Myositis Patients That Respond Better To Rtuximab Therapy
Abstract Number: 959

Interleukin 10 Negatively Correlates With Glycoprotein VI-Related Platelet Activation In Rheumatoid Arthritis (RA): A Novel Potential Target Of Cardiovascular Morbidity In RA
Abstract Number: 1887

Interleukin-1 Receptor Antagonist (IL-1Ra) Plasma Levels Predict Radiographic Progression Of Symptomatic Knee Osteoarthritis Over 24 Months
Abstract Number: 934

Interleukin-12B Is Up-Regulated By Decoy Receptor 3 In Specifically Rheumatoid Synovial Fibroblasts
Abstract Number: 2493

Interleukin-17 Serum Levels Are Associated With Markers Of Systemic Inflammation In Patients With Active Ankylosing Spondylitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].